“New Cholesterol-Lowering Drug Increases Problems”
Sold under the name of Praluent, alirocumab received FDA approval in July of 2015. It is a new class of cholesterol lowering drug, which increases our livers ability to soak up and remove low-density lipoprotein (LDL; the so called bad cholesterol). Praluent is supposed to be for those who do not respond to older statin medications or who have had adverse reactions to statins. Surprisingly, Praluent causes higher incidence of many of the same side effects as older satins. Most cholesterol-lowing drugs and are called “statins” and drug manufacturers plan to “statinize” the planet. Yet, there is some scientific evidence that higher cholesterol levels can be linked to varied health and survival benefits. There isn’t good science to support the notion that the lowest cholesterol levels are the best overall good health recommendation. Researchers at Texas A&M University have discovered that lower cholesterol levels can actually reduce muscle gain with exercising. There was a significant association of dietary cholesterol and change in strength.
